We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+42.3%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$151M
AUM Growth
-$61.4M
Cap. Flow
-$24.1M
Cap. Flow %
-15.93%
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
1
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$17.1M
2
RPTX
Repare Therapeutics
RPTX
+$4.66M
3
ADVM
Adverum Biotechnologies
ADVM
+$2.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
1
Monte Rosa Therapeutics
GLUE
$1.33B
$68.7M 45.49%
4,382,687
-1,270,235
-22% -$17.1M
LENZ
2
LENZ Therapeutics
LENZ
$166M
$42.5M 28.14%
2,656,888
– –
JBIO
3
Jade Biosciences
JBIO
$1.33B
$23.5M 15.59%
1,525,820
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$5.02B
$7.8M 5.17%
148,831
– –
CTNM
5
Contineum Therapeutics
CTNM
$573M
$6.2M 4.11%
542,628
– –
SKYE icon
6
Skye Bioscience
SKYE
$20M
$1.51M 1%
2,007,704
– –
TPST icon
7
Tempest Therapeutics
TPST
$14.4M
$774K 0.51%
269,772
– –
ADVM
8
DELISTED
Adverum Biotechnologies
ADVM
– –
-506,821
Closed -$2.3M
RPTX
9
DELISTED
Repare Therapeutics
RPTX
– –
-2,646,657
Closed -$4.66M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return
CL
CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return

Versant Venture Management's Q4 2025 Portfolio in Review

As of Q4 2025, Versant Venture Management held 9 positions worth $151M, down 29% from $212M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $24.1M in Q4 2025, closing 2 positions and reducing 1 holding. Its most notable exit was Repare Therapeutics, an estimated $4.66M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management's biggest Q4 2025 reduction was Monte Rosa Therapeutics, cutting an estimated $17.1M.
  • Versant Venture Management fully exited Repare Therapeutics in Q4 2025, selling an estimated $4.66M.
  • Versant Venture Management's ten largest holdings make up 100% of its $151M portfolio in Q4 2025.
  • Versant Venture Management opened 0 new positions and closed 2 in Q4 2025.
  • Versant Venture Management's portfolio value fell 29% quarter-over-quarter to $151M.

Based on Versant Venture Management's 13F filing for Q4 2025, filed 12 Feb 2026.